Clinical trial
A Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms.
NCT06235216 is registered in ClinicalTrials.gov with Grupo Espanol de Tumores Neuroendocrinos as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms.
- Lead sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 13, 2024
- Completion date
- December 31, 2027
- Enrollment
- 42 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
anaplastic thyroid cancer, differentiated thyroid cancer